897016-96-5

Basic information

• Product Name: 4-(4-broMo-3-fluorobenzyl)Morpholine
• Synonyms: 4-(4-broMo-3-fluorobenzyl)Morpholine;N-(4-Bromo-3-fluorobenzyl)morpholine
• CAS NO: 897016-96-5
• Molecular Formula: C₁₁H₁₃BrFNO
• Molecular Weight: 274.1294232
• Product Categories: alkyl bromide|alkyl Fluorine
• Mol File: 897016-96-5.mol
• Article Data: 6

Chemical Properties

• Melting Point: 42-43℃
• Appearance: /
• CAS DataBase Reference: 4-(4-broMo-3-fluorobenzyl)Morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-broMo-3-fluorobenzyl)Morpholine(897016-96-5)
• EPA Substance Registry System: 4-(4-broMo-3-fluorobenzyl)Morpholine(897016-96-5)

Safety Data

• Hazardous Substances Data: 897016-96-5(Hazardous Substances Data)

Upstream product

• 897016-95-4 (4-bromo-3-fluorophenyl)(morpholino)methanone 
• 110-91-8 morpholine 
• 133059-43-5 4-bromo-3-fluorobenzaldehyde 
• 127425-73-4 1-bromo-4-(bromomethyl)-2-fluorobenzene 

Downstream Products

• 1252575-59-9 5-fluoro-N-(2-fluoro-4-(morpholinomethyl)phenyl)-4-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl)pyrimidin-2-amine 
• 897016-97-6 4-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine 

Relevant articles and documents

SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS

The present invention relates to LpxC antibacterial compounds of Formula (1A), corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions:, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.

Anti-Malarial Agents

The present invention relates to a novel class of quinolone-4-carboxamide Pf3D7 inhibitors of general formula (I) (Formula (I)) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and in the treatment of malaria in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

Imidazole Substituted Pyrimidines

A compound of formula (I) wherein R1 is hydrogen or fluoro; R2 and R3 are independently selected from hydrogen or methyl, or a pharmaceutically acceptable salt thereof; pharmaceutical formulations containing said compound; the use of said compound in therapy; the use for the treatment of conditions associated with glycogen synthase kinase-3 related disorders, such as Alzheimer's disease, as well as methods of treatment of said disorders, comprising administering to subjects in need of such treatment, a therapeutically effective amount of said compound.